Concept

Ferring Pharmaceuticals

Summary
Ferring Pharmaceuticals is a Swiss multinational biopharmaceutical company specialising in areas such as reproductive health, maternal health, gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years. Headquartered in Saint-Prex, Switzerland, Ferring has its own manufacturing facilities in several European countries, in South America, China, India, and the United States. Founded in 1950, privately-owned Ferring employs over 7,000 employees worldwide, has its own operating subsidiaries in more than 50 countries and markets its products in over 100 countries. The company was founded by Dr. Frederik Paulsen Sr and Dr Eva Paulsen in Malmö, Sweden, in 1950, initially as the Nordiska Hormon Laboratoriet, renamed Ferring in 1954. A ferring in Frisian is a person from the island Föhr off the western coast of Germany. Mr. Paulsen's family originates from that island. The first major breakthrough was the synthetic production of oxytocin and vasopressin in 1961. With further growth and expansion, the headquarters moved to Copenhagen, Denmark, and subsequently to Switzerland. In October 2011, Ferring acquired Cytokine PharmaSciences Inc. (CPSI) and its UK subsidiary Controlled Therapeutics (Scotland) Ltd., a global biopharmaceutical company with a particular focus in obstetrics. In August 2016, the company announced it would acquire the phase III sciatica candidate drug - Condoliase (SI-6603) from Seikagaku for approximately 95million.InApril2018,FerringannounceditsacquisitionofRebiotixInc.aninnovativebiotechnologycompanyandpioneerinthefieldofthehumanmicrobiome.InNovember2019,FerringPharmaceuticalsandBlackstoneLifeSciencesannouncedthejointinvestmentofover95 million. In April 2018, Ferring announced its acquisition of Rebiotix Inc. an innovative biotechnology company and pioneer in the field of the human microbiome. In November 2019, Ferring Pharmaceuticals and Blackstone Life Sciences announced the joint investment of over 570 million USD in an investigational novel gene therapy in late stage development for patients with high-grade, Bacillus Calmette-Guérin (BCG) unresponsive, non-muscle invasive bladder cancer (NMIBC). Ferring and Blackstone spun out a new gene therapy company called Fergene to bring the therapy to patients.
About this result
This page is automatically generated and may contain information that is not correct, complete, up-to-date, or relevant to your search query. The same applies to every other page on this website. Please make sure to verify the information with EPFL's official sources.